Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according…
Novartis is spending $165 million upfront to license a preclinical amyloid-targeting program for Alzheimer’s disease from SciNeuro. The…